Congressman Sanford Bishop

Representing the 2nd District of Georgia


Jul 18, 2018
Press Release
WASHINGTON, DC – Today, Congressman Sanford D. Bishop, Jr. (GA-02) and Congressman Pete Sessions (TX-32) were joined by Congressman Fred Upton (MI-06) and Congressman Gus Bilirakis (FL-12) in introducing groundbreaking “Eye Bonds” legislation, the Faster Treatments and Cures for Eye Diseases Act (H.R. 6421), to fund translational research and advance treatments and cures for blindness and other eye conditions.
The Faster Treatments and Cures for Eye Diseases Act would establish a pilot program to create unique financial instruments called Eye Bonds. These bonds would finance packages of loans to projects at small labs, universities and other centers. They have the potential to mobilize as much as $1 billion in research funding by incentivizing private investment in conjunction with public research dollars which would receive repayment priority.
“I have long been an advocate for those living with a disability, whether it is supporting their access to jobs and a productive and robust quality of life or supporting vital health research, and I know that it is essential that we find new ways to tackle old problems,” said Congressman Bishop. “We have had federally funded research sitting on the shelf, waiting for private investors to put it into practice, for far too long. The Eye Bonds created by the Faster Treatments and Cures for Eye Diseases Act will give health research the boost it needs to help Americans. These bonds will fund research that has the potential to deliver new treatments for a range of conditions including macular degeneration, glaucoma, blindness caused by diabetes and sickle cell disease, and many others. And this is just the first step, as similar bonds could be created to support groundbreaking research into a host of other conditions such as cancer, Alzheimer’s and Parkinson's disease.”
“Eye-Bonds would pioneer a new way to bring long-term, low-risk private investors into the biomedical arena that should cost the taxpayer virtually nothing,” said Congressman Sessions. “Translational biomedical research advances the initial, basic research taxpayers fund into the cures and treatments private companies develop and patients need. However, this research often takes years of clinical trials and testing, leaving much of the research funded by the government on the shelf instead of out in the clinic. There are times when the private sector needs a push and there is a proper role for the government to play in making these critical advancements — this is one of those instances.”
“I’ve always been a strong proponent of finding cures and treatments for patients in need, and this bill will help do just that,” said Congressman Upton. “This bipartisan effort will kick-start funding of innovative biomedical programs to help families and patients in my home state of Michigan, and across the country, suffering from vision impairment and blindness. I’m glad to join with my colleagues to introduce this exciting piece of legislation and look forward to our continued work together.”
“As a visually impaired American, I am very proud to support this initiative because it reflects out-of-the box thinking about new ways to spur the development of cures and treatments that could potentially transform lives," said Congressman Bilirakis. "This creative approach to funding innovative treatments to cure blindness holds great promise as a model that can be expanded to support the development of cures for other diseases, which is extremely exciting.”
Projects supported by Eye Bonds would fund research for treatments and cures for a wide range of blinding conditions and causes of severe vision impairment, including glaucoma and sickle-cell anemia retinopathy. In addition, “Eye Bonds” funded research would help with treatment for the severe vision trauma that is sadly one of the most common injuries suffered by our warriors in Iraq, Afghanistan, and other theaters of war. Research on treatments and cures for age-related macular degeneration, diabetes retinopathy, and many causes of childhood vision loss could also see significant support from Eye Bond funding. 
In the U.S. there are more than 4 million adults and almost half-a-million children who are blind or have severely impaired vision. Supporters believe Eye Bonds are urgently needed to overcome what is known as “The Valley of Death,” which refers to research that is never translated into treatments to help humans because of funding issues. This legislation would lift up research from the valley, expediting potential new treatments to the people who need them.
Congressman Bishop and his colleagues believe the success of the Eye Bonds could have the potential to provide an alternative way to mobilize federal resources that could be deployed for many other diseases and disabilities, such as cancer, Alzheimer’s and Parkinson's disease.
The Faster Treatments and Cures for Eye Diseases Act would implement numerous safeguards to ensure taxpayers’ interests are protected and to quickly reimburse taxpayers for the small initial outlays to start the project. The pilot program would require that the National Eye Institute (NEI), part of the National Institutes of Health (NIH), select eligible projects so that only legitimate, viable projects would receive funding. Furthermore, taxpayers are repaid first – not last – as researchers advance treatments and repay their obligations. The legislation also requires controls at each stage of this pilot program, which would follow rules from the Department of Health and Human Services and Department Treasury to maximize taxpayer protections, speed cures, and prevent conflicts of interest.
Eye Bonds legislation has received the support of the Foundation Fighting Blindness, National Alliance for Eye and Vision Research, and Blinded Veterans of America.